Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8853)
All Articles published online
|
Publishing Process of This Article
|
Feb 6, 2016 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Attar BM, Van Thiel DH. Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther 2016; 7(1): 33-40 [PMID: 26855810 DOI: 10.4292/wjgpt.v7.i1.33] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v7/i1/33.htm |
| Number | Citing Articles |
| 1 |
Sara Lo Menzo, Enrico Biagi, Mariachiara Di Nuzzo, Anastasio Grilli, Carlo Contini. SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient. Annals of Hepatology 2018; 17(4): 661 doi: 10.5604/01.3001.0012.0950
|
| 2 |
Tung Huynh, Johnathan Zhang, Ke-Qin Hu. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. Journal of Clinical and Translational Hepatology 2018; 6(3): 1 doi: 10.14218/JCTH.2018.00014
|
| 3 |
Martha Shumway, Anne F. Luetkemeyer, Marion G. Peters, Mallory O. Johnson, Tessa M. Napoles, Elise D. Riley. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 2019; 31(11): 1340 doi: 10.1080/09540121.2019.1587353
|
| 4 |
Sichan He, Ian Lockart, Maryam Alavi, Mark Danta, Behzad Hajarizadeh, Gregory J. Dore. Systematic review with meta‐analysis: effectiveness of direct‐acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2020; 51(1): 34 doi: 10.1111/apt.15598
|
| 5 |
Jessica Taaffe, David Wilson. Mobilising a global response to hepatitis: Lessons learned from the HIV movement. Global Public Health 2018; 13(4): 473 doi: 10.1080/17441692.2016.1233989
|
| 6 |
Jason Gummow, Makutiro G. Masavuli, Zelalem A. Mekonnen, Yanrui Li, Danushka K. Wijesundara, Ashish C. Shrestha, Ilia Voskoboinik, Eric J. Gowans, Branka Grubor-Bauk. Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. Vaccines 2020; 8(1): 53 doi: 10.3390/vaccines8010053
|
| 7 |
Melanie Mallory, David Hillyard. Clinical Virology Manual. 2016; : 351 doi: 10.1128/9781555819156.ch25
|
| 8 |
Nahed A. Makhlouf, Mohamed Farouk, Hanan Mohamed Nafeh, Ahmad Farooq Alsayed Hasanain, Mohamed Ahmed El-Mokhtar, Helal F. Hetta, Mohamed A. Mekky, Mohamed Alboraie, Hussein ELamin, Ahmed Medhat Nasr. NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy. Egyptian Liver Journal 2021; 11(1) doi: 10.1186/s43066-021-00080-0
|
| 9 |
Xiuzhu Gao, Mengru Zhan, Liquan Wang, Yanhua Ding, Junqi Niu. <p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>. Journal of Hepatocellular Carcinoma 2020; : 347 doi: 10.2147/JHC.S279657
|
| 10 |
Kosuke Matsumoto, Hisamitsu Miyaaki, Masanori Fukushima, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma, Kazuhiko Nakao. The impact of single‑nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct‑acting antiviral drugs for hepatitis C infection. Biomedical Reports 2021; 16(2) doi: 10.3892/br.2021.1492
|
| 11 |
Elia Moreno-Cubero, Juan-Ramón Larrubia. Specific CD8<sup>+</sup> T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World Journal of Gastroenterology 2016; 22(28): 6469-6483 doi: 10.3748/wjg.v22.i28.6469
|
| 12 |
Ozge Cevik, Dan Li, Erdene Baljinnyam, Dinesh Manvar, Erica M. Pimenta, Gulam Waris, Betsy J. Barnes, Neerja Kaushik-Basu. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma. Journal of Biological Chemistry 2017; 292(52): 21676 doi: 10.1074/jbc.M117.792721
|
| 13 |
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo, Yuri Sanchez Gonzalez. Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infectious Diseases and Therapy 2016; 5(4): 491 doi: 10.1007/s40121-016-0134-x
|
| 14 |
Dalia Morales-Arraez, Manuel Hernandez-Guerra, Felicitas Diaz-Flores, Yolanda Nieto-Bujalance, Jose Garcia-Dopico, Alejandro Jimenez, Enrique Quintero. Hepatitis C virus media coverage favorably impacts on antibody testing in the non-interferon era. Journal of Public Health 2021; 43(2): 385 doi: 10.1093/pubmed/fdz149
|
| 15 |
Tsung-Lung Tsai, Huei-Min Jhou, Frank S Fan. Conspicuous Response to Direct-Acting Antivirals in Chronic Hepatitis C-related Immune Thrombocytopenia: A Case Report. Cureus 2022; doi: 10.7759/cureus.24193
|
| 16 |
Sandra J. Page, Maria M. Rivera, David E. Kleiner, Xiongce Zhao, Sungyoung Auh, Elaine F. Remmers, Theo Heller. Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCV‐related liver damage. Hepatology Communications 2017; 1(9): 973 doi: 10.1002/hep4.1103
|
| 17 |
Natalia Echeverría, Pilar Moreno, Juan Cristina. Human Virology in Latin America. 2017; : 333 doi: 10.1007/978-3-319-54567-7_17
|